Диссертация (1174220), страница 42
Текст из файла (страница 42)
Age-Period-Cohort Modeling of MultipleSclerosis Incidence Rates in Kuwait: 1980-2014. // Neuroepidemiology. – 2017. - 49(3-4). Р.152-159.81.Akkad D.A., Bellenberg B., Esser S. et al. Multiple sclerosis risk loci correlate with cervical cordatrophy and may explain the course of disability. // Neurogenetics. – 2015. - 16(3).
- Р.161-168.82.Alonso A., Hernan M.A.. Temporal trends in the incidence of multiple sclerosis: a systematicreview. // Neurology. – 2008. – 71. - Р.129–135.83.Amato M. P., Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis:impact of disease-modifying drugs. // CNS Drugs. – 2015. - 9(3). - Р. 207–220.84.Apolone G., De Carli G., Brunetti M., Garattini S.. Health-related quality of life (HR-QOL) andregulatory issues: an assessment of the European Agency for the Evaluation of MedicinalProducts (EMEA) recommendations on the use of HR-QOL measures in drug approval. //Pharmaco Economics.
– 2001. – 19. - Р.187–195.85.Arnon R., Aharoni R. Neurogenesis and neuroprotection in the CNS - fundamental elements inthe effect of Glatiramer acetate on treatment of autoimmune neurological disorders. // MolNeurobiol. – 2007. – 36. - Р. 245-253.17786.Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis.
Part I: the role ofinfection. // Ann Neurol. - 2007a. - 61: Р. 288–299.87.Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part II:noninfectious factors. //Ann Neurol. - 2007b. – 61. - Р. 504–513.88.Auricchio F., Scavone C., Cimmaruta D. et al. Drugs approved for the treatment of multiplesclerosis: review of their safety profile. // Expert Opin Drug Saf. – 2017. - 16(12).
- Р. 13591371.89.Baranzini S.E., Wang J., Gibson R.A. et al. Genome-wide association analysis of susceptibilityand clinical phenotype in multiple sclerosis. // Human Molecular Genetics. – 2009. – 18. - Р.767-778.90.Baranzini S.E., Oksenberg J.R. The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. //Trends Genet. – 2017.
- 33(12). - Р. 960-970.91.Baranzini S.E. Revealing the genetic basis of multiple sclerosis: are we there yet? // Curr OpinGenet Dev. – 2011. - 21(3). - Р. 317-324.92.Bashinskaya V.V., Kulakova O.G., Boyko A.N. et al. A review of genome-wide associationstudies for multiple sclerosis: classical and hypothesis-driven approaches. // Hum Genet. 2015b. - 134(11-12). - Р. 1143-1162.93.Bashinskaya V.V., Kulakova O.G., Kiselev I.S.
et al. GWAS-identified multiple sclerosis riskloci involved in immune response: validation in Russians. // J Neuroimmunol. - 2015a. – 282. Р. 85-91.94.Baumstarck K., Boyer L., Boucekine M. et al. Measuring the Quality of Life in patients withmultiple sclerosis in clinical practice: A necessary challenge. Mult Scler Int.
– 2013. - 13:524894.95.Baumstarck K., Boyer L., Boucekine M. et al. Measuring the quality of life in patients withmultiple sclerosis in clinical practice: a necessary challenge. // Mult Scler Int. - 2013a. – 2013. 524894.96.Baumstarck K., Pelletier J., Butzkueven H. et al. Health-related quality of life as an independentpredictor of long-term disability for patients with relapsing-remitting multiple sclerosis.
// Eur JNeurol. - 2013b. - 20(6). - Р. 907-914.97.Baumstarck-Barrau K., Pelletier J., Simeoni M.C., Auquier P. French validation of the multiplesclerosis international quality of life questionnaire. // Revue Neurologique. – 2011. - 167(6-7). Р. 511–521.98.Beiske A.G., Baumstarck K., Nilsen R.M., Simeoni M.C. Validation of the multiple sclerosisinternationalqualityoflife(MusiQoL)questionnaireActaNeurologicaScandinavica. – 2011.
- 125(3). - Р. 171–179.inNorwegianpatients.//17899.Benedict R.H.B., DeLuca J., Enzinger C. et al. Neuropsychology of multiple sclerosis: lookingback and moving forward. // J Int Neuropsychol Soc. – 2017. - 23(9-10). - Р. 832-842100. Benito-Leon J., Mitchell A.J., Rivera-Navarro .J, Morales-Gonzalez J.M. Impaired health-relatedquality of life predicts progression of disability in multiple sclerosis.
// Europ J Neurol. – 2012. 20(1). - Р. 79–86.101. Benito-León J.., Morales JM., Rivera-Navarro J.. Health-related quality of life and itsrelationship to cognitive and emotional functioning in multiple sclerosis patients. // Europ JNeur. – 2002. - 9(5). - Р. 497–502.102. Berge T.., Leikfoss I.S., Brorson I.S. et al. The multiple sclerosis susceptibility genes TAGAPand IL2RA are regulated by vitamin D in CD4+ T cells. // Genes Immun. – 2016. - 17(2).
- Р.118-127.103. Berger J.R. Classifying PML risk with disease modifying therapies. // Mult Scler Relat Disord. –2017. – 12. - Р. 59-63.104. Bittner S., Ruck T., Wiendl H. et al. Targeting B cells in relapsing-remitting multiple sclerosis:from pathophysiology to optimal clinical management. // Ther Adv Neurol Disord. – 2017.
10(1). - Р. 51-66.105. Bloomgren G., Richman S., Hotermans C. et al. Risk of natalizumab-associated progressivemultifocal leukoencephalopathy. // N Engl J Med. – 2012. – 366. - Р. 1870–1880.106. Blozik E., Rapold R., Eichler K., Reich O.
Epidemiology and costs of multiple sclerosis inSwitzerland: an analysis of health-care claims data, 2011-2015. // Neuropsychiatr Dis Treat. 2017. - 13. - Р. 2737-2745.107. Bohlega S., Inshasi J., Al Tahan A.R, Madani A.B., Qahtani H., Rieckmann P. Multiple sclerosisin the Arabian Gulf countries: a consensus statement. // J Neurology. – 2013.
- 260(12). - Р.2959-2963.108. Booth D.R., Arthur A.T., Teutsch S.M. et al.; The Southern MS Genetics Consortium. Geneexpression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis ofprimary progressive multiple sclerosis. // J.
Mol. Med. – 2005. – 83. - Р. 822-830.109. Boyko A. Long-term results of the first line DMT depend on the presence of minimal MSactivity during first years of therapy: data of 15 years observation. // Multiple Sclerosis &Demyelinating Diseases. – 2016. - 1:14 DOI 10.1186/s40893-016-0015-x110. Boyko A.N., Arnold D., Cohen J., et al. Alemtuzumab-associated infusion reactions in CAREMS II.
// European Journal of Neurology. – 2012. - 19 (Suppl. 1). – Р. 715.111. Boyko A.N., Gusev E.I., Sudomoina M.A. et al. Association and linkage of juvenile MS withHLA-DR2(15) in Russians. // Neurology. – 2002. – 58. - Р. 658-660.179112. Boyko A.N., Tatarinova M.Y., Alekseeva T.G. et al. Quality of life indexes in dependence of thedisease severity in multiple sclerosis patients from the Russian population.
// Multiple Sclerosis.– 1999. – 5. – Р. 142.113. Boyko A.N. Clinical effects and tolerability of high-dose, high-frequency recombinant interferonβ-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence. //Expert Opin. Biol. Ther. – 2010. – 10. - Р. 653-666.114. Brown R.F., Tennant C.C., Dunn S.M., Pollard J.D. A review of stress-relapse interactions inmultiple sclerosis: important features and stress-mediating and -moderating variables. // MultScler.
– 2005. - Aug; ll(4). - Р. 477-84.115. Browne P., Chandraratna D., Angood C. et al. Atlas of Multiple Sclerosis 2013: A growingglobal problem with widespread inequity. // Neurology. – 2014. - 83(11). - Р. 1022-1024.116. Burwick R.M., Ramsay, P.P., Haines, J.L. et al. APOE epsilon variation in multiple sclerosissusceptibility and disease severity : some answers. Neurology.
– 2006. – 66. - Р. 1373–1383.117. Caillier S.J., Briggs F., Cree B.A. et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5genes in multiple sclerosis. // J Immunol. – 2008. – 181. - Р. 5473-5480.118. Calabresi P.A., Kieseier B.C., Arnold D.L. et al. Pegylated interferon beta-1a in relapsingremitting multiple sclerosis (ADVANCE): a randomized, phase 3, double-blind study. // LancetNeurol.
– 2014.- 13(7). - Р. 657-665.119. Casetta I., Riise T., Nortvedt M. et al. Gender differences in health-related quality of life inmultiple sclerosis. // Mult Scler. – 2009. - 15(11). - Р. 1339–1346.120. Cella D.F., Dineen K., Arnason B. et al. Validation of the Functional Assessment of MultipleSclerosis quality of life instrument. // Neurol.
– 1996.- 47. - Р. 129-139.121. Chun J., Hartung H. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. //Clin Neuropharacol. – 2010. – 33. - Р. 91–101.122. Cohen B.A., Rivera V.M. PRISMS: the story of a pivotal clinical trial series in multiplesclerosis. // Curr Med Res Opin. – 2010.
- 26(4). - Р. 827-838.123. Cohen J., Barkhof F., Comi G. et al. Oral fingolimod or intramuscular interferon for relapsingmultiple sclerosis. // N Eng J Med – 2010. – 362. - Р. 402–415.124. Cohen J.A., Coles A.J., Arnold D.L. et al. Alemtuzumab versus interferon beta 1a as first-linetreatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase3 trial. // Lancet. – 2012. – 380.
- Р. 1819-1828.125. Coles A.J., Twyman C.L., Arnold D.L. et al. Alemtuzumab for patients with relapsing multiplesclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. // Lancet. –2012. – 380. - Р. 1829-1839.180126. Confavreux C., Li D.K., Freedman M.S. et al. Long-term follow-up of a phase 2 study of oralteriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
// MultScler. – 2012. – 18. - Р. 1278-1289.127. Costa S.L., Genova H.M., De Luca J., Chiaravalloti N.D. Information processing speed inmultiple sclerosis: Past, present, and future // Mult Scler. – 2017. - 23(6). - Р. 772-789.128. Costelloe L., O'Rourke K., Kearney H. et al. The patient knows best: significant change in thephysical component of the Multiple Sclerosis Impact Scale (MSIS‐29 physical). // J NeurolNeurosurg Psychiatry. – 2007. - 78(8).
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
